Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Kostine

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Annals of the Rheumatic Diseases|August 14, 2018
Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and MouraThierry Schaeverbeke, Marie Kostine
Drugs|June 30, 2017
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?Bernard Bannwarth, Marie Kostine
Drugs|April 3, 2014
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Bernard Bannwarth, Marie Kostine
Annals of the Rheumatic Diseases|July 29, 2018
Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon <i>et al</i>Marie Kostine, Thierry Schaeverbeke,
Annals of the Rheumatic Diseases|June 24, 2018
Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud <i>et al</i>Marie Kostine, Christophe Richez, Thierry Schaeverbeke, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 11, 2013
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritisBernard Bannwarth, Marie Kostine, Nicolas Poursac
Joint Bone Spine|November 26, 2013
Are there concerns about generic medicines in rheumatology?Bernard Bannwarth, Marie Kostine, Nicolas Poursac
European Journal of Cancer (Oxford, England : 1990)|April 25, 2017
Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?Marie Kostine, Chloé Stavris, Laurent Chiche
Joint Bone Spine|November 13, 2012
Licensing of antirheumatic drugs: are the EMA and FDA on the same page?Bernard Bannwarth, Driss Berdaï, Marie Kostine
Arthritis & Rheumatology (Hoboken, N.J.)|October 15, 2019
ReplyAlice Tison, Marie Kostine, Divi Cornec
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Annals of the Rheumatic Diseases|August 14, 2018
Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and MouraThierry Schaeverbeke, Marie Kostine
Drugs|June 30, 2017
Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?Bernard Bannwarth, Marie Kostine
Drugs|April 3, 2014
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Bernard Bannwarth, Marie Kostine
Annals of the Rheumatic Diseases|July 29, 2018
Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon <i>et al</i>Marie Kostine, Thierry Schaeverbeke,
Annals of the Rheumatic Diseases|June 24, 2018
Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud <i>et al</i>Marie Kostine, Christophe Richez, Thierry Schaeverbeke, et al.
Expert Opinion on Drug Metabolism & Toxicology|April 11, 2013
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritisBernard Bannwarth, Marie Kostine, Nicolas Poursac
Joint Bone Spine|November 26, 2013
Are there concerns about generic medicines in rheumatology?Bernard Bannwarth, Marie Kostine, Nicolas Poursac
European Journal of Cancer (Oxford, England : 1990)|April 25, 2017
Opportunistic autoimmunity secondary to immunotherapy and melanoma: Back to ABCDE?Marie Kostine, Chloé Stavris, Laurent Chiche
Joint Bone Spine|November 13, 2012
Licensing of antirheumatic drugs: are the EMA and FDA on the same page?Bernard Bannwarth, Driss Berdaï, Marie Kostine
Arthritis & Rheumatology (Hoboken, N.J.)|October 15, 2019
ReplyAlice Tison, Marie Kostine, Divi Cornec
Pageof 7